Faisal Khurshid
Stock Analyst at Jefferies
(4.98)
# 48
Out of 4,598 analysts
244
Total ratings
63.5%
Success rate
72.7%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintained: Hold | $330 → $230 | $220.33 | +4.39% | 2 | Jul 31, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintained: Buy | $25 | $15.38 | +62.55% | 1 | Jul 31, 2026 | |
| SMMT Summit Therapeutics | Maintained: Hold | $17 → $15 | $13.05 | +14.99% | 4 | Jul 24, 2026 | |
| INSM Insmed | Maintained: Buy | $175 → $160 | $98.45 | +62.52% | 5 | Jul 13, 2026 | |
| ONC BeOne Medicines AG | Upgraded: Buy | $333 → $380 | $313.77 | +21.11% | 3 | Jul 12, 2026 | |
| ABVX ABIVAX Société Anonyme | Upgraded: Buy | $90 → $158 | $124.78 | +26.62% | 4 | Jul 1, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $29 → $30 | $19.31 | +55.36% | 2 | Jun 30, 2026 | |
| VSTM Verastem | Maintained: Buy | $15 → $8 | $5.69 | +40.60% | 2 | Jun 23, 2026 | |
| PTCT PTC Therapeutics | Upgraded: Buy | $76 → $85 | $68.12 | +24.79% | 2 | May 27, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $290 | $243.45 | +19.12% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $37 | $19.24 | +92.31% | 2 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 | $182.45 | -23.27% | 2 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $21 | $10.09 | +108.13% | 1 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $103 → $120 | $80.06 | +49.89% | 14 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $38.86 | +41.53% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $94 | $118.43 | -20.63% | 1 | Mar 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $9.02 | +99.56% | 1 | Mar 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $118 → $110 | $100.31 | +9.66% | 16 | Mar 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $33 | $32.43 | +1.76% | 1 | Mar 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $12.76 | +17.55% | 1 | Mar 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $142 | $102.78 | +38.16% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $21 | $15.93 | +31.83% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $4 | $5.83 | -31.39% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12 | $23.22 | -48.32% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 → $40 | $26.73 | +49.64% | 11 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 → $9 | $3.80 | +136.84% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.492 | - | 17 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.30 | - | 11 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.52 | - | 11 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $17.90 | - | 17 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.10 | - | 13 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $132.28 | - | 2 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $94.93 | - | 10 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $2 | $7.29 | -72.57% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $1.28 | +134.38% | 17 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $4.42 | -77.38% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $1.04 | +92.31% | 14 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $74.50 | n/a | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $1.58 | n/a | 7 | Nov 9, 2023 |
Alnylam Pharmaceuticals
Jul 31, 2026
Maintained: Hold
Price Target: $330 → $230
Current: $220.33
Upside: +4.39%
Monte Rosa Therapeutics
Jul 31, 2026
Maintained: Buy
Price Target: $25
Current: $15.38
Upside: +62.55%
Summit Therapeutics
Jul 24, 2026
Maintained: Hold
Price Target: $17 → $15
Current: $13.05
Upside: +14.99%
Insmed
Jul 13, 2026
Maintained: Buy
Price Target: $175 → $160
Current: $98.45
Upside: +62.52%
BeOne Medicines AG
Jul 12, 2026
Upgraded: Buy
Price Target: $333 → $380
Current: $313.77
Upside: +21.11%
ABIVAX Société Anonyme
Jul 1, 2026
Upgraded: Buy
Price Target: $90 → $158
Current: $124.78
Upside: +26.62%
Viridian Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $29 → $30
Current: $19.31
Upside: +55.36%
Verastem
Jun 23, 2026
Maintained: Buy
Price Target: $15 → $8
Current: $5.69
Upside: +40.60%
PTC Therapeutics
May 27, 2026
Upgraded: Buy
Price Target: $76 → $85
Current: $68.12
Upside: +24.79%
Ascendis Pharma
May 6, 2026
Maintained: Buy
Price Target: $290
Current: $243.45
Upside: +19.12%
May 1, 2026
Maintained: Buy
Price Target: $40 → $37
Current: $19.24
Upside: +92.31%
Apr 10, 2026
Maintained: Buy
Price Target: $140
Current: $182.45
Upside: -23.27%
Mar 30, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $10.09
Upside: +108.13%
Mar 25, 2026
Maintained: Buy
Price Target: $103 → $120
Current: $80.06
Upside: +49.89%
Mar 16, 2026
Initiated Coverage: Buy
Price Target: $55
Current: $38.86
Upside: +41.53%
Mar 15, 2026
Downgraded: Hold
Price Target: $94
Current: $118.43
Upside: -20.63%
Mar 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $9.02
Upside: +99.56%
Mar 15, 2026
Initiated Coverage: Buy
Price Target: $118 → $110
Current: $100.31
Upside: +9.66%
Mar 15, 2026
Downgraded: Hold
Price Target: $33
Current: $32.43
Upside: +1.76%
Mar 15, 2026
Initiated Coverage: Buy
Price Target: $15
Current: $12.76
Upside: +17.55%
Dec 15, 2025
Maintained: Buy
Price Target: $142
Current: $102.78
Upside: +38.16%
Dec 15, 2025
Reiterated: Buy
Price Target: $20 → $21
Current: $15.93
Upside: +31.83%
Nov 7, 2025
Downgraded: Hold
Price Target: $5 → $4
Current: $5.83
Upside: -31.39%
Oct 23, 2025
Reiterated: Hold
Price Target: $12
Current: $23.22
Upside: -48.32%
Oct 22, 2025
Upgraded: Buy
Price Target: $29 → $40
Current: $26.73
Upside: +49.64%
Oct 10, 2025
Initiated Coverage: Buy
Price Target: $7 → $9
Current: $3.80
Upside: +136.84%
Sep 30, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.492
Upside: -
Sep 30, 2025
Reiterated: Buy
Price Target: n/a
Current: $15.30
Upside: -
Sep 30, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.52
Upside: -
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $17.90
Upside: -
Sep 25, 2025
Reiterated: Buy
Price Target: n/a
Current: $14.10
Upside: -
Sep 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $132.28
Upside: -
Sep 11, 2025
Reiterated: Buy
Price Target: n/a
Current: $94.93
Upside: -
Aug 18, 2025
Maintained: Buy
Price Target: $4 → $2
Current: $7.29
Upside: -72.57%
Aug 12, 2025
Reiterated: Buy
Price Target: $3
Current: $1.28
Upside: +134.38%
Aug 7, 2025
Reiterated: Hold
Price Target: $1
Current: $4.42
Upside: -77.38%
Aug 7, 2025
Reiterated: Hold
Price Target: $2
Current: $1.04
Upside: +92.31%
Jul 28, 2025
Reiterated: Buy
Price Target: n/a
Current: $74.50
Upside: n/a
Nov 9, 2023
Reiterated: Hold
Price Target: $2
Current: $1.58
Upside: n/a